Research Analysts Set Expectations for DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Denali Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($3.15) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the firm posted ($0.68) earnings per share.

Several other equities analysts have also recently issued reports on DNLI. Wedbush lowered their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Oppenheimer decreased their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Morgan Stanley started coverage on shares of Denali Therapeutics in a report on Friday, March 7th. They issued an "overweight" rating and a $33.00 target price on the stock. HC Wainwright cut their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, William Blair raised Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $33.71.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock traded down $0.38 during trading on Tuesday, hitting $14.55. 1,998,468 shares of the company's stock traded hands, compared to its average volume of 1,133,641. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $33.33. The business has a 50-day simple moving average of $14.15 and a 200-day simple moving average of $17.85. The stock has a market capitalization of $2.11 billion, a P/E ratio of -5.27 and a beta of 1.32.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds have recently modified their holdings of the business. Strs Ohio bought a new position in Denali Therapeutics in the 1st quarter worth $324,000. SCS Capital Management LLC bought a new stake in Denali Therapeutics during the first quarter valued at about $2,692,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Denali Therapeutics by 88.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock worth $91,996,000 after buying an additional 3,184,042 shares in the last quarter. Woodline Partners LP raised its stake in shares of Denali Therapeutics by 13.5% in the first quarter. Woodline Partners LP now owns 113,517 shares of the company's stock worth $1,543,000 after buying an additional 13,517 shares during the period. Finally, Empowered Funds LLC raised its stake in shares of Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after buying an additional 2,052 shares during the period. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.